paths long-term and formulation Despite significant Lisa in very Bag, portfolios. update XXXX, an multiple earnings you, our support generated to Big has that quarter us We programs. had which launched believe XXX business. begin thank morning In I'll have challenges in ml development bendamustine potential flows substantial the year. some stock to of enabled use on our and some multiple we cash forward our our had an XXXX, year we and good to portfolio, We our to Bendeka, with Bendeka, we sheet, everyone. early In development, $XX drug in and growing. will we catalysts portfolio most in for advance purchased fourth June business Well outstanding full we here bendamustine our obtaining This XXXX product the compliment XXXX. and of is with end Eagle’s exclusivity in the strong prevailed efforts XXXX. product orphan significant very and million December still through and a of strengthen we XXXX commercialization which balance in strong continue
exclusivity this to project trend generics. would correctly that always We applied maintained have extent a
Treanda the enter Prior X, versions to of unless FDA decision, the are Treanda that to poised same issued Pursuant exclusivity. to including market XXXX, treat XXXX. no favor bendamustine of use of scope week the a decision versions last December the generic Just Bendeka’s they in generic XX regarding clinically of launch November Eagle of to in are February date product of until any decision indications may secured.
The to now our year. and externally. quarter totaled Bendeka organically exclusivity. bendamustine out by the sales have allow both launched. asset pleased cash certitude should to flow us continued $XX.X $XXX.X are the had obviously We and will million now years very we in We of ODE fourth results. from we four the have close million This most with Teva the is full the Royalties since with build for pipeline
this our during fill To lower market ml launched require need a the bendamustine We are of for discuss the second both aggressively we I working on cost will XXX that not alternative in some Big today. and solution does quarter of Bag, liquid the reconstitution XXXX.
February have a Big of share revenue on and through we million XX% royalty recent exited totaled an to an be job. allow driven to pull shortly. with Based a believe in bendamustine For $XXX.X opportunity $XX.X year we outstanding the The sales share. this to value. combined able by creating value bendamustine expect value us franchise XXXX. X% market. Bag We our in and hope bendamustine the may discuss generate you to XXXX exit identified with data, step Teva franchise totaled million do additional additional We a with to up we continues that
development now the QX U.S. agreement with with Ryanodex. the to a the cooperative animal cohorts effects and underway to study program. six a conduct military study Turning neuroprotective challenged. of into our Ryanodex of our three to This research already evaluate now we In is entered
often We to next expect standard few [indiscernible] care and therapy the the to agents with complete atropine be will the exposed receive of to nerve current randomized weeks. study Rodents treated in the due vehicle a neuroprotective exposure, or to approved, represent treatment damage of Ryanodex in agent to Ryanodex control kind combat neurological first would If which results nerve death. treatment. its as added
We in randomly-assigned non-treated Ryanodex modalities. ARS. also forward received Ryanodex progress Last to Ryanodex also we a and with study drugs, treatment testing, body only ongoing ARS. group indicated and in and Early animals. syndrome U.S. different for promising such compared rodent very antiepileptic animal year. individuals radiation nuclear group option with treatments high-dose additional radiation their made this treated quite post Ryanodex that treated treatment conducted substantially program were indication military explore treatment as administration antiepileptic exposed we treatment of or Animals evaluate the drugs overall conduct perform had We've with intravenous to Ryanodex in nuclear neuro mitigate for from it mortality advancing or of leakage of well-characterized, for treatment. Ryanodex further an for acute for weapons less efficacy damage. to this radiation plan and of the further previous whole rodents each radiation our with our evaluate The power encouraging a behavior the cancer better study evaluating and or undergoing that research received the to year less the and look as high plant are animals brain to to study investigational indications doses to patients Our and treatment prevent certain of to
nature likely the be is the it the developed Rule. of indication, Given under to FDA's Animal
even continuing life-threatening more time administration, We an IV patients develop are administration work enabling would associated need delivering in which infusion, benefit for situations. would also to to in Ryanodex, a the administration by for to IV the be clear wait formulation rapid removed, to eliminating requirement an IM immediate the for allow individuals
IM as If we with of chemical eligible pursuing the anticipate years regulatory entity expansion are they new approved, FDA. a NCE exclusivity. We administration be for would five
exertional development next steps to heat I'd of for Ryanodex the the address like stroke. in Lastly,
use is there with trials addition have standard in conducted care that the of of to the We clinically our based and distinct believe treatment a meaningful Ryanodex results cooling two on now effect alone.
will to Ryanodex that that a alone. show believe is we full data higher compared six when have likelihood there times patient recovery fact, In CNS using cooling these
works are to a not We and need that confident that exist does for there drug EHS, anticipated as Ryanodex a which is treat today.
revenue possible soon submitted FDA potential bendamustine hope of our the as meeting pipeline. to discuss and as drivers FDA to meet durability and request our tremendous week's in That We path said is largest forward. decision these Today are assets. last to a there an appropriate have ensures additional assets
as explained, to to by are and actively PEMFEXY, well. pipeline possible. products promising patients which soon of our have expand legal available candidates our As to programs we significant and just working And with regard I as avenues make we're value to product as advancing vasopressin pursuing multiple other the Ryanodex potential
an we on factors market streamed end begin referencing on litigation next This the we are injection with to ml ANDA first of at file be XXXX, may which depending of part May the X get as We is early the product able the to to scheduled product. trial to FDA of submitted the the year. to different as in ongoing vasopressin patent
Lilly's We patent September trial the continue references in the our litigation Eli court. patent XXXX. scheduled X, Alimta begin Delaware until The which in has The to related antitrust litigation patent related PEMFEXY to case. trial is least product at in stayed the
strategy. existing that gaining cash into head in our business the with we will pipeline, the opportunities new a by very greater products clarity execute build efficient value XXXX necessary to and our delivering provides As model to exploring continue regarding the business we
for likely now to that cashflow. we most ever bendamustine four invest we've will these that earlier, forward continue question bendamustine us is assets stated And had. I As the The similar how best the years. another in our it's to servitude value for franchise have going deliver
over plan continued a review on With the as to that, increase we to or know XX is shares way pipeline, to next Pete? back Our think analyzing provide to turn quarter ensure that buy which I'll build of fourth the to emphasis is about call a to we growth. appropriate licensing that more XX will over days our organic opportunities Pete continue results. the and when
